Study on gemcitabine-related hematologic adverse drug reaction by automatic surveillance

KOU Wei; GUO Dai-hong; WANG Wei-lan; JIA Wang-ping; WANG Xiao-yu

Abstract：[AbstrAct]Objective:To study the incidence of hematologic adverse drug reaction caused by gemcitabine.Methods:The research objects were screened out by adverse drug events' active surveillance and assessment system developed by our hospital. The collected data of the hospitalized patients in General Hospital of PLA who received gemcitabine from January 1, 2016 to June 30, 2016 were analyzed retrospectively. The incidence of hematologic ADR caused by gemcitabine and the related factors were investigated. results: A total of 620 cases using gemcitabine were automatically monitored. Positive alarm rate of leukopenia, neutropenia, thrombocytopenia and anemia were 92.11%, 98.73%, 95.08% and 85.00% respectively. Incidence of leukopenia, neutropenia, thrombocytopenia and anemia induced by gemcitabine were 33.18%, 18.48%, 10.49% and 18.48% respectively. And the incidences of severe ADR were 4.27%, 4.50%, 3.44% and 0 respectively. By analyzing the data of the three modules as a whole, it was found that overall incidence of gemcitabine-related hematologic ADR was 45.29%, and the adverse reactions occurred mostly in the age of 45 to 75 years old. There was no signiifcant difference in incidence of hematologic ADR among the gender, age, BMI and frequencies of hospitalization (P > 0.05).conclusion:By using the automatic surveillance and assessment system, pharmacists can effectively and accurately screen the hematologic ADR induced by anti-cancer drugs and make guidance for rational drug use in order to reduce and avoid the occurrence of adverse reactions. The rate of gemcitabine-related hematologic ADR is high and hematological indexes should be closely monitored in the course of clinical drug use to prevent the occurrence of adverse reactions.